Director at Lucid Diagnostics (LUCD) granted 123K restricted shares
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
PALUMBO JOHN R reported acquisition or exercise transactions in this Form 4 filing.
Lucid Diagnostics Inc. director John R. Palumbo received a grant of 123,000 shares of common stock as a restricted stock award under the company’s 2018 Equity Plan. The award was granted at $0.00 per share and increases his directly held common stock to 338,000 shares.
The restricted stock has a single vesting date of May 20, 2029 and is subject to forfeiture if the required service period is not completed, meaning Palumbo must remain in the specified service role through that date for the shares to fully vest.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
PALUMBO JOHN R
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 123,000 | $0.00 | -- |
Holdings After Transaction:
Common Stock — 338,000 shares (Direct)
Footnotes (1)
- [object Object]
FAQ
What did Lucid Diagnostics (LUCD) director John R. Palumbo report on this Form 4?
John R. Palumbo reported receiving a grant of 123,000 shares of Lucid Diagnostics common stock. The shares are a restricted stock award under the 2018 Equity Plan and are not an open-market purchase or sale.
What forfeiture conditions apply to the new LUCD restricted stock grant?
The restricted stock is subject to forfeiture if the requisite service period is not completed. Palumbo must satisfy the service requirement through May 20, 2029 for the 123,000-share grant to fully vest and be retained.